AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2020
Dec 15, 2020
34238_dirs_2020-12-15_b54b6644-7f25-41a4-89cf-90691a007314.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2020-12-11
Reporting Person: HESTERBERG LYNDAL K. (CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-11 | Common Stock | A | 6603 | — | Acquired | 7477 | Direct |
Footnotes
F1: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share.
More from Insight Molecular Diagnostics Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 17
Call Transcript
2026
May 13
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Call Transcript
2026
Apr 15
Call Transcript
2026
Mar 26
Regulatory Filings
2026
Feb 26
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Feb 12
Capital/Financing Update
2026
Feb 12